Cited by 65Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchGenetic Associations and Epidemiology

Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme control analysis of Alzheimer’s disease

Open access
Tesi, Niccolò, van der Lee, Sven J., Hulsman, Marc, Jansen, Iris E., Stringa, Najada, van Schoor, Natasja, Meijers-Heijboer, Hanne, Huisman, Martijn +4 more·2019·European Journal of Human Genetics

Published version of a preprint

Abstract

Abstract The detection of genetic loci associated with Alzheimer’s disease (AD) requires large numbers of cases and controls because variant effect-sizes are mostly small. We hypothesized that variant effect-sizes should increase when individuals who represent the extreme ends of a disease spectrum are considered, as their genomes are assumed to be maximally enriched or depleted with disease-associated genetic variants. We used 1,073 extensively phenotyped AD cases with relatively young age at onset as extreme cases (66.3±7.9 years), 1,664 age-matched controls (66.0±6.5 years) and 255 cognitively healthy centenarians as extreme controls (101.4±1.3 years). We estimated the effect-size of 29 variants that were previously associated with AD in genome-wide association studies. Comparing extreme AD-cases with centenarian-controls increased the variant effect-size relative to published effect-sizes by on average 1.90-fold ( SE =0.29, p =9.0×10 −4 ). The effect-size increase was largest for the rare high-impact TREM2 (R74H) variant (6.5-fold), and significant for variants in/near ECHDC3 (4.6-fold), SLC24A4-RIN3 (4.5-fold), NME8 (3.8-fold), PLCG2 (3.3-fold), APOE-ε2 (2.2-fold) and APOE - ε4 (2.0-fold). Comparing extreme phenotypes enabled us to replicate the AD association for 10 variants ( p <0.05) in relatively small samples. The increase in effect-sizes depended mainly on using centenarians as extreme controls: the average variant effect-size was not increased in a comparison of extreme AD cases and age-matched controls (0.94-fold, p =6.8×10 −1 ), suggesting that on average the tested genetic variants did not explain the extremity of the AD-cases. Concluding, using centenarians as extreme controls in AD case-controls studies boosts the variant effect-size by on average two-fold, allowing the replication of disease-association in relatively small samples.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41431-018-0273-5

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The initial genetic results for P522R and decreased AD risk were replicated by various independent cohorts.

    “The initial genetic results were replicated by various independent cohorts (160, 161, 162).”

    From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [161]

    The Discussion says this study provides independent replication of previously reported AD-associated variants in a Dutch population. Table 2 reports an association between the PLCG2 variant and AD, consistent with decreased risk, but the paper describes one independent Dutch study—not replication by various independent cohorts. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N., Meijers-Heijboer, H., Huisman, M., Scheltens, P., Reinders, M. J. T., van der Flier, W. M., & Holstege, H.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Amsterdam Neuroscience (NL)
  • Amsterdam Public Health (NL)
  • Delft University of Technology (NL)
Corresponding author
Holstege, Henne
Venue
European Journal of Human Genetics
Published
2018-09-26
Volume
27
Issue
2
Pages
244-253
ISSN
  • 1018-4813 (ISSN-L)
  • 1476-5438
OpenAlex
W2949491829
Cited by
65
References
54
Citations by year
2026: 2 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 2 · 2018: 1
FWCI
4.64
Type
journal article
Language
en
Open access
Locations
  • European Journal of Human Genetics (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • VU Research Portal (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Research Repository (Delft University of Technology) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • ZonMw (733051061)
  • Stichting Dioraphte (VSM 14 04 1402)
  • Alzheimer Nederland (WE09.2014–03)
  • Amsterdam Neuroscience
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease, centenarians, replication of genetic associations, APOE ε4, APOE ε2, PLCγ2, age of onset, genetic loci
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Sample Size, Patient Selection, Polymorphism, Single Nucleotide, Control Groups, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review